A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial

This study provides a proof-of-concept for generating bactericidal antibodies against FetA after OMV vaccination in humans. Prevalence-based choice of PorA and FetA types can be used to formulate a vaccine for broad protection against MenB disease.